A Phase 1 interventional study of Venetoclax and Alvocidib in Acute Myeloid Leukemia (AML), sponsored by AbbVie. Completed at 14 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-02-01.
Sponsored by AbbVie · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 202 studies testing venetoclax in Leukemia, Myeloid, Acute — 116 open to participants now, 144 under way, 21 of them phase 3. venetoclax · Leukemia, Myeloid, Acute.
Among the 202 studies testing venetoclax in Leukemia, Myeloid, Acute, this one is the 142nd largest by enrollment, is one of 11 that started in 2018, is one of 38 in phase 1, and was the 17th registered.
3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 816 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →116 of the 202 studies testing venetoclax in Leukemia, Myeloid, Acute are open now, in 12 countries. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States, Puerto Rico
Ages 18–59
National Cancer Institute (NCI) · Sites in United States, Puerto Rico
Ages 60+
Virginia Commonwealth University · Sites in United States
Ages 18+
The First Affiliated Hospital of Soochow University · Sites in China
Ages 18+
Beijing 302 Hospital · Sites in China
Ages 18–70
By country, each count listing its studies:
venetoclax: first FDA approval 2016 (VENCLEXTA), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
202 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 66 · Phase 2 127 · Phase 3 26 · Phase 4 5
First in 2010; this study’s year is marked. 11 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 36 is close to the median of 40 across 3,006 interventional studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 57 across the 202 interventional studies. Of the 46 that completed or were terminated, 15 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 202 have an industry lead sponsor. The 10 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
43 studies in Leukemia, Myeloid, Acute by AbbVie: 4 open now, 10 under way, 3 of them phase 3. Of 31 finished, 7 (23%) have results posted.
Among the 43 studies in Leukemia, Myeloid, Acute by AbbVie, this one is the 24th largest by enrollment of the 32 interventional ones that give a count, is one of 5 that started in 2018, is one of 16 in phase 1, and was the 16th registered.
AbbVie’s Leukemia, Myeloid, Acute studies by the year they started, since 2010.
38 of the studies testing venetoclax in Leukemia, Myeloid, Acute that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07264010Phase 3Nanfang Hospital, Southern Medical UniversitySorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study | 2026-12-30 |
| NCT07486479Phase 3The First Affiliated Hospital of Soochow UniversityVenetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML | 2026-12-31 |
| NCT05183035Phase 3PedAL BCU, LLCVenetoclax in Children With Relapsed Acute Myeloid Leukemia (AML) | 2027-02 |
| NCT03844048Phase 3AbbVieAn Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial | 2027-08 |
| NCT07514936Phase 3Chinese PLA General HospitalVenetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid Leukaemia | 2027-09-30 |
Add all 38 to your calendar (.ics) → With an account.
Among the 202 studies testing venetoclax in Leukemia, Myeloid, Acute, from their registry updates:
Among AbbVie’s 43 in Leukemia, Myeloid, Acute:
This tab as a report to print or save as PDF → With an account.
An open-label, dose-escalation study to assess the safety and pharmacokinetics (PK), to determine the dose limiting toxicity (DLT) and the recommended Phase 2 dose (RPTD), and to assess the preliminary efficacy of alvocidib with venetoclax when co-administered in participants with relapsed or refractory (R/R) acute myeloid leukemia (AML).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Venetoclax administered orally once daily (QD) and Alvocidib administered as an intravenous infusion on Days 1, 2, and 3 for all 28-day treatment cycles. Different combinations of dose levels for venetoclax and alvocidib may be explored.
Drug: Venetoclax · Drug: Alvocidib
tablet, oral
Also known as: ABT-199
Intravenous
Also known as: Flavopiridol
Tmax of venetoclax
Time to maximum plasma concentration (Tmax) of venetoclax
Time frame: Approximately 32 days after first dose of study drug
Clearance of Alvocidib
Clearance (CL) of alvocidib
Time frame: Approximately 32 days after first dose of study drug
AUC0-∞ of Alvocidib
Area under the plasma concentration-time curve from 0 to infinity (AUC0-∞) post-dose of alvocidib
Time frame: Approximately 32 days after first dose of study drug
Cmax of Venetoclax
Maximum plasma concentration (Cmax) of venetoclax
Time frame: Approximately 32 days after first dose of study drug
Half-life (t1/2) of Alvocidib
Half-life (t1/2) of alvocidib
Time frame: Approximately 32 days after first dose of study drug
AUC0-24 Post-dose of Venetoclax
Area under the plasma concentration-time curve from 0 to 24 hours (AUC24) post-dose of venetoclax.
Time frame: Approximately 32 days after first dose of study drug
Cmax of Alvocidib
Maximum plasma concentration (Cmax) of alvocidib.
Time frame: Approximately 32 days after first dose of study drug
AUCt Post-dose of Alvocidib
Area under the plasma concentration-time curve from time zero to time t (AUCt) post-dose alvocidib.
Time frame: Approximately 32 days after first dose of study drug
Dose Escalation Phase: Recommended Phase 2 dose (RPTD) for Venetoclax and Alvocidib
RPTD will be determined using available safety and pharmacokinetics data upon completion of the dose escalation phase.
Time frame: Minimum first cycle of dosing (up to 28 days)
Complete Response (CR) Rate
CR is defined as the proportion of participants with documented complete response (CR) based on International Working Group (IWG) criteria.
Time frame: Up to approximately 8 months
Combined CR Rate
Combined CR rate is defined as CR + CRi (CR with incomplete blood count recovery) based on IWG criteria.
Time frame: Up to approximately 8 months
Objective Response Rate (ORR)
ORR is defined as the proportion of participants with documented partial response (PR) or better based on IWG criteria.
Time frame: Up to approximately 18 months
Plan to share: No
Ran from May 2018 to primary completion in Jan 2021, 31 months.
Of 183 industry-sponsored phase 1 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 62. This study's 31 months is below that.
Counting every sponsor, half of 491 studies reached it within 49 months; a quarter within 31 and three quarters within 77.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Venetoclax · Alvocidib